Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne.

In this episode Tim chats all things regenerative medicine with Paul Anderson, founder and CEO of Orthocell (ASX:OCC).

A player in the booming regenerative medicine space, Orthocell is commercialising cell therapies to treat soft tissue and musculoskeletal disorders.

Orthocell’s core product Celgro is a lattice made from a natural collagen to promote tissue growth such as bone and joint cartilage repair, as well as nerve damage as a result of accidents.

The company is also working to improve dental implant procedures.

Tune in to hear the pair discuss targeting the growth of musculoskeletal disorders, new markets created by ageing populations and OCC’s Avatar moment.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!